{"id":"anlotinib-hydrochloride-capsules-penpulimab-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Immune-related adverse events (from PD-1 inhibitor)"}]},"_chembl":{"chemblId":"CHEMBL5572229","moleculeType":null,"molecularWeight":"443.91"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anlotinib inhibits multiple receptor tyrosine kinases (VEGFR, FGFR, RET, KIT) involved in tumor angiogenesis and growth signaling. Penpulimab blocks programmed death receptor-1 (PD-1) on T cells, releasing immune checkpoint inhibition and allowing enhanced anti-tumor immunity. The combination targets both tumor vasculature/growth and immune evasion mechanisms.","oneSentence":"Anlotinib is a multi-target tyrosine kinase inhibitor that blocks angiogenesis and tumor growth, while Penpulimab is a PD-1 inhibitor that enhances anti-tumor immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:46.099Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced non-small cell lung cancer"},{"name":"Other solid tumors (phase 3 evaluation)"}]},"trialDetails":[{"nctId":"NCT05975645","phase":"PHASE1","title":"A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-08-15","conditions":"Advanced Hepatocellular Carcinoma","enrollment":29},{"nctId":"NCT06886347","phase":"PHASE1","title":"Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Chen Xiaozhong","startDate":"2023-07-07","conditions":"Metastatic Nasopharyngeal Carcinoma","enrollment":47},{"nctId":"NCT06341530","phase":"PHASE2","title":"Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-01-31","conditions":"Non-small Cell Lung Cancer","enrollment":33},{"nctId":"NCT06010901","phase":"PHASE1","title":"A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-01-13","conditions":"Colorectal Cancer","enrollment":75},{"nctId":"NCT05494060","phase":"PHASE2","title":"XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-03-16","conditions":"Carcinoma, Gastrointestinal Diseases, Stomach Cancer","enrollment":80},{"nctId":"NCT05862337","phase":"PHASE3","title":"Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-05-10","conditions":"Hepatocellular Carcinoma","enrollment":480},{"nctId":"NCT05033587","phase":"PHASE2","title":"Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-09","conditions":"MGMT-Unmethylated Glioblastoma","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Anlotinib hydrochloride capsules, Penpulimab injection","genericName":"Anlotinib hydrochloride capsules, Penpulimab injection","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anlotinib is a multi-target tyrosine kinase inhibitor that blocks angiogenesis and tumor growth, while Penpulimab is a PD-1 inhibitor that enhances anti-tumor immune response. Used for Advanced non-small cell lung cancer, Other solid tumors (phase 3 evaluation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}